Clinical Trial Update: A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study in healthy volunteers comparing the relative bioavailability of different formulations of GSK2018682, a sphingosine-1-phosphate re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GSK2018682 (GSK2018682)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Status: COMPLETED